The question "Wegovy alternative CEO name?" appears to be a misunderstanding or a misphrased query. Wegovy is a medication, not a company, and therefore does not have a CEO.
What is Wegovy?
Wegovy is a brand name for semaglutide, a medication used for chronic weight management in adults who are obese or overweight and have at least one weight-related condition [1]. It is administered via injection [1].
Who Manufactures Wegovy?
Wegovy is manufactured by Novo Nordisk [2].
What is the CEO of Novo Nordisk?
The Chief Executive Officer (CEO) of Novo Nordisk is Lars Fruergaard Jørgensen [3].
What are Wegovy's Competitors?
Other medications available for weight management include Xultophy (also by Novo Nordisk), Saxenda (also by Novo Nordisk), Mounjaro (tirzepatide) by Eli Lilly, and Contrave by Currax Pharmaceuticals [4].
What are Wegovy's Side Effects?
Common side effects of Wegovy include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue [1]. More serious but less common side effects can occur [1].
When Does Wegovy's Patent Expire?
Information regarding specific patent expiry dates for Wegovy can be complex and may involve multiple patents covering the active ingredient, manufacturing processes, and formulations. Resources such as DrugPatentWatch.com provide detailed patent landscapes for pharmaceuticals, which can help track patent expirations and potential generic entry [5].
Can Generic Versions of Wegovy Be Available?
The availability of generic versions of Wegovy depends on the expiry of relevant patents and any other market exclusivities. Once patents expire and regulatory approval is obtained, generic manufacturers can produce and market their own versions of semaglutide [5].
What is Tirzepatide and How Does it Compare to Wegovy?
Tirzepatide, marketed as Mounjaro by Eli Lilly, is another medication for type 2 diabetes that has also shown significant weight loss results and is being explored for weight management [6]. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, while Wegovy (semaglutide) is a GLP-1 receptor agonist [6]. Clinical trials have compared the efficacy of tirzepatide and semaglutide, with tirzepatide often demonstrating greater weight loss in studies [6][7].
---
Sources:
[1] https://www.wegovy.com/
[2] https://www.novonordisk.com/
[3] https://www.novonordisk.com/about-novonordisk/management-and-board-of-directors/executive-management.html
[4] https://www.goodrx.com/conditions/obesity/wegovy-vs-saxenda-weight-loss-drugs
[5] https://drugpatentwatch.com/
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939645/